Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 5/2024

01-05-2024 | Review Article

Regulation of cancer progression by CK2: an emerging therapeutic target

Authors: Shakeel Hussain, Yilei Guo, Yu Huo, Juanjuan Shi, Yongzhong Hou

Published in: Medical Oncology | Issue 5/2024

Login to get access

Abstract

Casein kinase II (CK2) is an enzyme with pleiotropic kinase activity that catalyzes the phosphorylation of lots of substrates, including STAT3, p53, JAK2, PTEN, RELA, and AKT, leading to the regulation of diabetes, cardiovascular diseases, angiogenesis, and tumor progression. CK2 is observed to have high expression in multiple types of cancer, which is associated with poor prognosis. CK2 holds significant importance in the intricate network of pathways involved in promoting cell proliferation, invasion, migration, apoptosis, and tumor growth by multiple pathways such as JAK2/STAT3, PI3K/AKT, ATF4/p21, and HSP90/Cdc37. In addition to the regulation of cancer progression, increasing evidence suggests that CK2 could regulate tumor immune responses by affecting immune cell activity in the tumor microenvironment resulting in the promotion of tumor immune escape. Therefore, inhibition of CK2 is initially proposed as a pivotal candidate for cancer treatment. In this review, we discussed the role of CK2 in cancer progression and tumor therapy.
Literature
1.
Pinna L. A historical view of protein kinase CK2. Cell Mol Biol Res. 1994;40:383–90.PubMed
2.
3.
Montenarh M, Götz C. Protein kinase CK2 and ion channels. Biomed Rep. 2020;13:1.CrossRef
4.
Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, et al. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem Cell Biol. 1999;31:941–9.PubMedCrossRef
5.
Yu H, Yang X, Tang J, Si S, Zhou Z, Lu J, et al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2α-mediated glycolysis. Molr Ther Nucleic Acids. 2021;23:27–41.CrossRef
6.
Kwon J, Zhang J, Mok B, Han C. CK2-Mediated phosphorylation upregulates the stability of USP13 and promotes ovarian cancer cell proliferation. Cancers. 2022;15:200.PubMedPubMedCentralCrossRef
7.
Siddiqui YH, Kershaw RM, Humphreys EH, Assis Junior E, Chaudhri S, Jayaraman P-S, et al. CK2 abrogates the inhibitory effects of PRH/HHEX on prostate cancer cell migration and invasion and acts through PRH to control cell proliferation. Oncogenesis. 2017;6:e293.PubMedPubMedCentralCrossRef
8.
Im D-K, Cheong H, Lee JS, Oh M-K, Yang KM. Protein kinase CK2-dependent aerobic glycolysis-induced lactate dehydrogenase A enhances the migration and invasion of cancer cells. Sci Rep. 2019;9:1–11.CrossRef
9.
Niechi I, Silva E, Cabello P, Huerta H, Carrasco V, Villar P, et al. Colon cancer cell invasion is promoted by protein kinase CK2 through increase of endothelin-converting enzyme-1c protein stability. Oncotarget. 2015;6:42749.PubMedPubMedCentralCrossRef
10.
Wu D, Sui C, Meng F, Tian X, Fu L, Li Y, et al. Stable knockdown of protein kinase CK2-alpha (CK2α) inhibits migration and invasion and induces inactivation of hedgehog signaling pathway in hepatocellular carcinoma Hep G2 cells. Acta Histochem. 2014;116:1501–8.PubMedCrossRef
11.
Qaiser F, Trembley JH, Kren BT, Wu JJ, Naveed AK, Ahmed K. Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function. J Cell Biochem. 2014;115:2103–15.PubMedPubMedCentralCrossRef
12.
Zhang L, Ruan X, Gu M, Mueck A. E2+ norethisterone promotes the PI3K–AKT pathway via PGRMC1 to induce breast cancer cell proliferation. Climacteric. 2022;25:467–75.PubMedCrossRef
13.
Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:1–9.
14.
Zhao N, Wang C, Guo P, Hou J, Yang H, Lan T, et al. CCDC106 promotes the proliferation and invasion of ovarian cancer cells by suppressing p21 transcription through a p53-independent pathway. Bioengineered. 2022;13:10957–73.PubMedCentralCrossRef
15.
Manni S, Carrino M, Piazza F. Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways. J Hematol Oncol. 2017;10:1–10.CrossRef
16.
Sun J, Zhang X, Sun Y. C1orf109 promotes malignant phenotype of liver cancer via wnt signaling pathway in a CK2-dependent manner. J Mol Histol. 2023;54:135–45.PubMedCrossRef
17.
Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, et al. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. J Hematol Oncol. 2013;6:1–15.CrossRef
18.
19.
Zou J, Luo H, Zeng Q, Dong Z, Wu D, Liu L. Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med. 2011;9:1–11.CrossRef
20.
Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, et al. mTORC1 and CK2 coordinate ternary and eIF4F complex assembly. Nat Commun. 2016;7:11127.PubMedPubMedCentralCrossRef
21.
Kim S, Ham S, Yang K, Kim K. Protein kinase CK2 activation is required for transforming growth factor β-induced epithelial–mesenchymal transition. Mol Oncol. 2018;12:1811–26.PubMedPubMedCentralCrossRef
22.
Turowec JP, Duncan JS, Gloor GB, Litchfield DW. Regulation of caspase pathways by protein kinase CK2: identification of proteins with overlapping CK2 and caspase consensus motifs. Mol Cell Biochem. 2011;356:159–67.PubMedCrossRef
23.
Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci. 2021;277: 119627.PubMedCrossRef
24.
Trembley J, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009;66:1858–67.PubMedPubMedCentralCrossRef
25.
Nipun V, Amin K. Recent advances in protein kinase CK2, a potential therapeutic target in cancer. Russ J Bioorg Chem. 2022;48:919–31.CrossRef
26.
27.
Ruzzene M, Bertacchini J, Toker A, Marmiroli S. Cross-talk between the CK2 and AKT signaling pathways in cancer. Adv Biol Regul. 2017;64:1–8.PubMedCrossRef
28.
Hwang S-Y, Chae J-I, Kwak A-W, Lee M-H, Shim J-H. Alternative options for skin cancer therapy via regulation of AKT and related signaling pathways. Int J Mol Sci. 2020;21:6869.PubMedPubMedCentralCrossRef
29.
Duan Y, Haybaeck J, Yang Z. Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers. 2020;12:2972.PubMedPubMedCentralCrossRef
30.
Chen J-F, Wu P, Xia R, Yang J, Huo X-Y, Gu D-Y, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Mol Cancer. 2018;17:1–16.CrossRef
31.
Trembley JH, Kren BT, Abedin MJ, Shaughnessy DP, Li Y, Dehm SM, et al. CK2 pro-survival role in prostate cancer is mediated via maintenance and promotion of androgen receptor and NFκB p65 expression. Pharmaceuticals. 2019;12:89.PubMedPubMedCentralCrossRef
32.
Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Can Res. 2002;62:6770–8.
33.
Borgo C, D’Amore C, Sarno S, Salvi M, Ruzzene M. Protein kinase CK2: A potential therapeutic target for diverse human diseases. Signal Transduct Target Ther. 2021;6:183.PubMedPubMedCentralCrossRef
34.
Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Finkenstädt D, et al. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget. 2014;5:2131.PubMedPubMedCentralCrossRef
35.
36.
37.
Zhang S, Yang Y-L, Wang Y, You B, Dai Y, Chan G, et al. CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 2014;33:1–12.
38.
Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84:359–69.PubMedCrossRef
39.
Mrozik KM, Blaschuk OW, Cheong CM, Zannettino ACW, Vandyke K. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer. 2018;18:1–16.CrossRef
40.
Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, et al. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer. 2004;90:1265–73.PubMedPubMedCentralCrossRef
41.
Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus: implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276:993–8.PubMedCrossRef
42.
Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000;20:5010–8.PubMedPubMedCentralCrossRef
43.
Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 2005;12:668–77.PubMedCrossRef
44.
Konicek BW, Dumstorf CA, Graff JR. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle. 2008;7:2466–71.PubMedCrossRef
45.
Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015;147:22–31.PubMedCrossRef
46.
Duncan JS, Turowec JP, Vilk G, Li SS, Gloor GB, Litchfield DW. Regulation of cell proliferation and survival: convergence of protein kinases and caspases. Biochimica et Biophysica Acta. 2010;1804:505–10.PubMedCrossRef
47.
Degli Esposti M, Ferry G, Masdehors P, Boutin JA, Hickman JA, Dive C. Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3. J Biol Chem. 2003;278:15749–57.PubMedCrossRef
48.
49.
Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4, 5, 6, 7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J. 2002;364:41–7.PubMedPubMedCentralCrossRef
50.
Yamane K, Kinsella TJ. Casein kinase 2 regulates both apoptosis and the cell cycle following DNA damage induced by 6-thioguanine. Clin Cancer Res. 2005;11:2355–63.PubMedCrossRef
51.
Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11:338–51.PubMedCrossRef
52.
Hashimoto A, Gao C, Mastio J, Kossenkov A, Abrams SI, Purandare AV, et al. Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in MiceCK2 INHIBITOR and MDSC. Can Res. 2018;78:5644–55.CrossRef
53.
Cheng P, Kumar V, Liu H, Youn J-I, Fishman M, Sherman S, et al. Effects of notch signaling on regulation of myeloid cell differentiation in cancernotch and myeloid cells in cancer. Can Res. 2014;74:141–52.CrossRef
54.
Reverendo M, Argüello RJ, Polte C, Valečka J, Camosseto V, Auphan-Anezin N, et al. Polymerase III transcription is necessary for T cell priming by dendritic cells. Proc Natl Acad Sci. 2019;116:22721–9.PubMedPubMedCentralCrossRef
55.
Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12:e7431.CrossRef
56.
Zhao X, Wei Y, Chu Y-Y, Li Y, Hsu J-M, Jiang Z, et al. Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function. Can Res. 2022;82:2185–95.CrossRef
57.
Ljunggren H-G, Malmberg K-J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329–39.PubMedCrossRef
58.
Kim H, Kim K, Lee K, Kim S, Kim J. Inhibition of casein kinase 2 enhances the death ligand-and natural kiler cell-induced hepatocellular carcinoma cell death. Clin Exp Immunol. 2008;152:336–44.PubMedPubMedCentralCrossRef
59.
Nelson N, Szekeres K, Iclozan C, Rivera IO, McGill A, Johnson G, et al. Apigenin: selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer. PLoS ONE. 2017;12: e0170197.PubMedPubMedCentralCrossRef
60.
Popescu M, Gurel Z, Ronni T, Song C, Hung KY, Payne KJ, et al. Ikaros stability and pericentromeric localization are regulated by protein phosphatase 1. J Biol Chem. 2009;284:13869–80.PubMedPubMedCentralCrossRef
61.
Yang W, Wei H, Benavides GA, Turbitt WJ, Buckley JA, Ouyang X, et al. Protein kinase CK2 controls CD8+ T cell effector and memory function during infection. J Immunol. 2022;209:896–906.PubMedCrossRef
62.
Wei H, Yang W, Hong H, Yan Z, Qin H, Benveniste EN. Protein kinase CK2 regulates B cell development and differentiation. J Immunol. 2021;207:799–808.PubMedCrossRef
63.
Piazza F, Manni S, Ruzzene M, Pinna L, Gurrieri C, Semenzato G. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia. 2012;26:1174–9.PubMedCrossRef
64.
Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 2006;108:1698–707.PubMedCrossRef
65.
Zhao M, Ma J, Zhu H-Y, Zhang X-H, Du Z-Y, Xu Y-J, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011;10:1–14.CrossRef
66.
Chou S-T, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, et al. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release. 2016;244:14–23.PubMedPubMedCentralCrossRef
67.
68.
Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. Targeting CK2 for cancer therapy. Anticancer Drugs. 2005;16:1037–43.PubMedCrossRef
69.
Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, et al. EGF-induced ERK activation promotes CK2-mediated disassociation of α-catenin from β-catenin and transactivation of β-catenin. Mol Cell. 2009;36:547–59.PubMedPubMedCentralCrossRef
70.
Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna L, et al. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene. 2007;26:6915–26.PubMedCrossRef
71.
Kramerov A, Saghizadeh M, Caballero S, Shaw L, Li Calzi S, Bretner M, et al. Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites. Mol Cell Biochem. 2008;316:177–86.PubMedPubMedCentralCrossRef
72.
Singh NN, Ramji DP. Protein kinase CK2, an important regulator of the inflammatory response? J Mol Med. 2008;86:887–97.PubMedCrossRef
73.
Ahmed K, Tawfic S, Yu S, Wang H, Faust R, Davis A. Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001;16:573–82.PubMed
74.
75.
76.
Son YH, Song JS, Kim SH, Kim J. Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch Pharmacal Res. 2013;36:840–5.CrossRef
77.
Perea SE, Baladrón I, Valenzuela C, Perera Y. CIGB-300: a peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation. In: Seminars in oncology. Amsterdam: Elsevier; 2018. p. 58–67.
78.
Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park S-M, et al. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Gastric Cancer. 2019;22:1153–63.PubMedCrossRef
79.
Wińska P, Widło Ł, Skierka K, Krzyśko A, Koronkiewicz M, Cieśla JM, et al. Simultaneous inhibition of protein kinase CK2 and dihydrofolate reductase results in synergistic effect on acute lymphoblastic leukemia cells. Anticancer Res. 2019;39:3531–42.PubMedCrossRef
80.
D’Amore C, Borgo C, Sarno S, Salvi M. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy–potential clinical relevance. Cell Oncol. 2020;43:1003–16.CrossRef
81.
McCarty MF, Assanga SI, Lujan LL. Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy. Med Hypotheses. 2020;141: 109723.PubMedCrossRef
82.
Yim H, Lee YH, Lee CH, Lee SK. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med. 1999;65:9–13.PubMedCrossRef
83.
Costa PSd, Ramos PS, Ferreira C, Silva JL, El-Bacha T, Fialho E. Pro-oxidant effect of resveratrol on human breast cancer MCF-7 cells is associated with CK2 inhibition. Nutr Cancer. 2022;74:2142–51.PubMedCrossRef
84.
Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A, et al. Protein kinase CK2 protects multiple myeloma cells from ER stress–induced apoptosis and from the cytotoxic effect of hsp90 inhibition through regulation of the unfolded protein response. Clin Cancer Res. 2012;18:1888–900.PubMedCrossRef
85.
Zhao Z, Wang L, Volk AG, Birch NW, Stoltz KL, Bartom ET, et al. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia. Genes Dev. 2019;33:61–74.PubMedPubMedCentralCrossRef
86.
Menyhart D, Gyenis L, Jurcic K, Roffey SE, Puri A, Jovanovic P, et al. Comparison of CX-4945 and SGC-CK2-1 as inhibitors of CSNK2 using quantitative phosphoproteomics: triple SILAC in combination with inhibitor-resistant CSNK2. Curr Res Chem Biol. 2023;3: 100041.CrossRef
87.
Li K, Zhou F, Zhou Y, Zhang S, Li Q, Li Z, et al. Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines. Int J Mol Med. 2019;44:437–46.PubMedPubMedCentral
88.
Lindenblatt D, Applegate V, Nickelsen A, Klußmann M, Neundorf I, Götz C, et al. Molecular plasticity of crystalline CK2α′ leads to KN2, a bivalent inhibitor of protein kinase CK2 with extraordinary selectivity. J Med Chem. 2021;65:1302–12.PubMedCrossRef
89.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Cancer J Clin. 2024;74:12–49.CrossRef
Metadata
Title
Regulation of cancer progression by CK2: an emerging therapeutic target
Authors
Shakeel Hussain
Yilei Guo
Yu Huo
Juanjuan Shi
Yongzhong Hou
Publication date
01-05-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02316-6

Other articles of this Issue 5/2024

Medical Oncology 5/2024 Go to the issue

Original Paper

YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis

Review Article

The role of SWI/SNF complexes in digestive system neoplasms

Original Paper

Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing

Review Article

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Original Paper

Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects

Correction

Correction to: Gingerol and/or sorafenib attenuates the DAB-induced HCC and hepatic portal vein dilatation via ATG4/CASP3 and COIIV/COX-2/NF-κB expression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits